Your browser doesn't support javascript.
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer.
Pinato, David J; Ferrante, Daniela; Aguilar-Company, Juan; Bower, Mark; Salazar, Ramon; Mirallas, Oriol; Sureda, Anna; Bertuzzi, Alexia; Brunet, Joan; Lambertini, Matteo; Maluquer, Clara; Pedrazzoli, Paolo; Biello, Federica; Lee, Alvin J X; Sng, Christopher C T; Liñan, Raquel; Rossi, Sabrina; Carmona-García, M Carmen; Sharkey, Rachel; Eremiev, Simeon; Rizzo, Gianpiero; Bain, Hamish Dc; Yu, Tamara; Cruz, Claudia A; Perachino, Marta; Saoudi-Gonzalez, Nadia; Fort-Culillas, Roser; Doonga, Kris; Fox, Laura; Roldán, Elisa; Zoratto, Federica; Gaidano, Gianluca; Ruiz-Camps, Isabel; Bruna, Riccardo; Patriarca, Andrea; Shawe-Taylor, Marianne; Fusco, Vittorio; Martinez-Vila, Clara; Berardi, Rossana; Filetti, Marco; Mazzoni, Francesca; Santoro, Armando; Delfanti, Sara; Parisi, Alessandro; Queirolo, Paola; Aujayeb, Avinash; Rimassa, Lorenza; Prat, Aleix; Tabernero, Josep; Gennari, Alessandra.
  • Pinato DJ; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
  • Ferrante D; Department of Translational Medicine, Unit of Medical Statistics, University of Piemonte Orientale, Novara, Italy.
  • Aguilar-Company J; Medical Oncology, Vall D'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; Infectious Diseases, Vall D'Hebron University Hospital, Barcelona, Spain.
  • Bower M; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.
  • Salazar R; Department of Medical Oncology, ICO L'Hospitalet, Oncobell Program (IDIBELL), CIBERONC, Hospitalet de Llobregat, Spain.
  • Mirallas O; Medical Oncology, Vall D'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.
  • Sureda A; Haematology Department, ICO Hospitalet, Hospitalet de Llobregat, IDIBELL, Universitat de Barcelona, Barcelona, Spain.
  • Bertuzzi A; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Brunet J; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain.
  • Lambertini M; Medical Oncology Department, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.
  • Maluquer C; Haematology Department, ICO Hospitalet, Hospitalet de Llobregat, IDIBELL, Universitat de Barcelona, Barcelona, Spain.
  • Pedrazzoli P; Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia Italy.
  • Biello F; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
  • Lee AJX; Cancer Division, University College London Hospitals, London, UK.
  • Sng CCT; Cancer Division, University College London Hospitals, London, UK.
  • Liñan R; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain.
  • Rossi S; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Carmona-García MC; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain.
  • Sharkey R; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.
  • Eremiev S; Medical Oncology, Vall D'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.
  • Rizzo G; Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Bain HD; Cancer Division, University College London Hospitals, London, UK.
  • Yu T; Cancer Division, University College London Hospitals, London, UK.
  • Cruz CA; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain.
  • Perachino M; Medical Oncology Department, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.
  • Saoudi-Gonzalez N; Medical Oncology, Vall D'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.
  • Fort-Culillas R; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain.
  • Doonga K; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.
  • Fox L; Department of Hematology, Vall D'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.
  • Roldán E; Medical Oncology, Vall D'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.
  • Zoratto F; Medical Oncology, St Maria Goretti Hospital, Latina, Italy.
  • Gaidano G; Division of Haematology, Department of Translational Medicine, University of Piemonte Orientale and Maggiore Della Carità Hospital, Novara, Italy.
  • Ruiz-Camps I; Infectious Diseases, Vall D'Hebron University Hospital, Barcelona, Spain.
  • Bruna R; Division of Haematology, Department of Translational Medicine, University of Piemonte Orientale and Maggiore Della Carità Hospital, Novara, Italy.
  • Patriarca A; Division of Haematology, Department of Translational Medicine, University of Piemonte Orientale and Maggiore Della Carità Hospital, Novara, Italy.
  • Shawe-Taylor M; Cancer Division, University College London Hospitals, London, UK.
  • Fusco V; Oncology Unit and Centro Documentazione Osteonecrosi, Azienda Ospedaliera "SS Antonio e Biagio e Cesare Arrigo", Alessandria, Italy.
  • Martinez-Vila C; Fundació Althaia Manresa, Manresa, Spain.
  • Berardi R; Medical Oncology, AOU Ospedali Riuniti, Polytechnic University of the Marche Region, Ancona, Italy.
  • Filetti M; Medical Oncology, St. Andrea Hospital, Rome, Italy.
  • Mazzoni F; Medical Oncology, Careggi University Hospital, Florence, Italy.
  • Santoro A; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 20090 Pieve Emanuele, Milan, Italy.
  • Delfanti S; Mesothelioma Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
  • Parisi A; Department of Life, Health & Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
  • Queirolo P; Melanoma and Sarcoma Medical Treatment Unit, IEO - Istituto Europeo di Oncologia, Milan, Italy.
  • Aujayeb A; Respiratory Department, Northumbria Healthcare NHS Foundation Trust, North Shields, UK.
  • Rimassa L; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 20090 Pieve Emanuele, Milan, Italy.
  • Prat A; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain.
  • Tabernero J; Medical Oncology, Vall D'Hebron University Hospital and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain.
  • Gennari A; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
Eur J Cancer ; 171: 64-74, 2022 08.
Article in English | MEDLINE | ID: covidwho-2178266
ABSTRACT

BACKGROUND:

Although SARS-CoV-2 vaccines immunogenicity in patients with cancer has been investigated, whether they can significantly improve the severity of COVID-19 in this specific population is undefined.

METHODS:

Capitalizing on OnCovid (NCT04393974) registry data we reported COVID-19 mortality and proxies of COVID-19 morbidity, including post-COVID-19 outcomes, according to the vaccination status of the included patients.

RESULTS:

2090 eligible patients diagnosed with COVID-19 between 02/2020 and 11/2021 were included, of whom 1930 (92.3%) unvaccinated, 91 (4.4%) fully vaccinated and 69 (3.3%) partially vaccinated. With the exception of a higher prevalence of patients from the UK (p = 0.0003) and receiving systemic anticancer therapy at COVID-19 diagnosis (p = 0.0082) among fully vaccinated patients, no demographics/oncological features were associated with vaccination status. The 14-days case fatality rate (CFR) (5.5% vs 20.7%, p = 0.0004) and the 28-days CFR (13.2% vs 27.4%, p = 0.0028) demonstrated a significant improvement for fully vaccinated patients in comparison with unvaccinated patients. The receipt of prior full vaccination was also associated with reduced symptomatic COVID-19 (79.1% vs 88.5%, p = 0.0070), need of COVID-19 oriented therapy (34.9% vs 63.2%, p < 0.0001), complications from COVID-19 (28.6% vs 39.4%, p = 0.0379), hospitalizations due to COVID-19 (42.2% vs 52.5%, p = 0.0007) and oxygen therapy requirement (35.7% vs 52%, p = 0.0036). Following Inverse Probability Treatment Weighting (IPTW) procedure no statistically significant difference according to the vaccination status was confirmed; however, all COVID-19 related outcomes were concordantly in favour of full vaccination. Among the 1228 (58.8%) patients who underwent a formal reassessment at participating centres after COVID-19 resolution, fully vaccinated patients experienced less sequelae than unvaccinated patients (6.7% vs 17.2%, p = 0.0320).

CONCLUSIONS:

This analysis provides initial evidence in support of the beneficial effect of SARS-CoV-2 vaccines against morbidity and mortality from COVID-19 in patients with cancer.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Diagnostic study / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: Eur J Cancer Year: 2022 Document Type: Article Affiliation country: J.ejca.2022.04.036

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Diagnostic study / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: Eur J Cancer Year: 2022 Document Type: Article Affiliation country: J.ejca.2022.04.036